HK1104790A1 - Pharmaceutical formulations of fenofibrate having improved bioavailability - Google Patents

Pharmaceutical formulations of fenofibrate having improved bioavailability

Info

Publication number
HK1104790A1
HK1104790A1 HK07113177.1A HK07113177A HK1104790A1 HK 1104790 A1 HK1104790 A1 HK 1104790A1 HK 07113177 A HK07113177 A HK 07113177A HK 1104790 A1 HK1104790 A1 HK 1104790A1
Authority
HK
Hong Kong
Prior art keywords
fenofibrate
pharmaceutical formulations
improved bioavailability
polethylene
polyethylene glycol
Prior art date
Application number
HK07113177.1A
Other languages
English (en)
Inventor
Itzhak E Lerner
Vered Rosenberger
Moshe Flashner-Barak
Anna Drabkin
Naomi Moldavski
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1104790A1 publication Critical patent/HK1104790A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK07113177.1A 2005-12-28 2007-12-03 Pharmaceutical formulations of fenofibrate having improved bioavailability HK1104790A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05258082A EP1803441B1 (fr) 2005-12-28 2005-12-28 Formulation pharmaceutique comprenant du fénofibrate ayant une biodisponibilité ameliorée

Publications (1)

Publication Number Publication Date
HK1104790A1 true HK1104790A1 (en) 2008-01-25

Family

ID=36260529

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07113177.1A HK1104790A1 (en) 2005-12-28 2007-12-03 Pharmaceutical formulations of fenofibrate having improved bioavailability

Country Status (8)

Country Link
EP (1) EP1803441B1 (fr)
AT (1) ATE429902T1 (fr)
DE (1) DE602005014258D1 (fr)
DK (1) DK1803441T3 (fr)
ES (1) ES2325450T3 (fr)
HK (1) HK1104790A1 (fr)
PL (1) PL1803441T3 (fr)
PT (1) PT1803441E (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2730231B1 (fr) 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
WO2002024169A1 (fr) * 2000-09-20 2002-03-28 Skyepharma Canada Inc. Procede de sechage par atomisation et compositions de fenofibrate
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP2085073A1 (fr) 2002-03-26 2009-08-05 Teva Pharmaceutical Industries Ltd. Microparticules de médicament
EP1680091B1 (fr) * 2003-10-10 2017-05-31 Veloxis Pharmaceuticals A/S Forme de dose solide comprenant un fibrate

Also Published As

Publication number Publication date
EP1803441A1 (fr) 2007-07-04
ES2325450T3 (es) 2009-09-04
PT1803441E (pt) 2009-06-08
ATE429902T1 (de) 2009-05-15
DE602005014258D1 (de) 2009-06-10
PL1803441T3 (pl) 2009-10-30
DK1803441T3 (da) 2009-08-03
EP1803441B1 (fr) 2009-04-29

Similar Documents

Publication Publication Date Title
HK1201437A1 (en) Sustained local anesthetic composition containing saib saib
WO2005020913A3 (fr) Preparations, conjugues, et combinaisons de medicaments dans le traitement de neoplasmes
WO2006128692A3 (fr) Derives de 2-oxo-1-pyrrolidine
TW200716206A (en) Unitary pharmaceutical dosage form
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
MY140739A (en) 2, 6-quinolinyl derivatives, processes for preparing them and their uses
RS50812B (sr) Suva granulisana kompozicija koja sadrži emtricitabin i tenofovir df
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
IL174655A0 (en) Drug containing (2r)-2-propyloctanoic acid as the active ingredient
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
WO2006072070A3 (fr) Formulations pharmaceutiques contenant des sels de gallium
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
BRPI0520821A2 (pt) formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
TW200731990A (en) Lipophilic anticancer drug compounds, compositions, and related methods
HRP20080422T3 (en) Satraplatin for treating resistant or refractory tumors
TW200716618A (en) Chemical compounds
WO2004064757A3 (fr) Agents facilitant l'absorption
HK1104790A1 (en) Pharmaceutical formulations of fenofibrate having improved bioavailability
TW200731964A (en) Pharmaceutical formulations of fenofibrate having improved bioavailability
TW200610526A (en) Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
WO2005110363A3 (fr) Systèmes et procédés pour préparer un dosage pharmaceutique en utilisant des compositions contenant des vésicules aqueuses
ZA200501010B (en) BenzoÄBÜchromeno-naphthyridin-7-one and pyranoÄ2'3':7,8ÜquinoÄ2,3-BÜquinoxalin-7-one compounds, process for their preparation and pharmaceutical compositions containing them.
ITTO20050301A1 (it) Formulazioni liquide orali contenenti citalopram
ZA200805656B (en) Prodrug ER²-selective substances, methods for the production thereof and pharmaceutical compositions containing said compounds
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121228